Other studies have shown efficacy of Ruxolitinib and Rapamycin (mTOR inhibitors) in CRLF2 and JAK aberrant B-ALL xenografts [58,66]. This evidence concerns the gene CRLF2 and acute lymphoblastic leukemia.